Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) ...

Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...

Is rhythm control underused in ATTR-CM? Drs Kevin Alexander and Ronald Witteles make the case for rethinking how we manage arrhythmias in this disease. Is rhythm control underused in ATTR-CM? Drs ...

Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival. In ‘Evaluating Transthyretin Stabilizers and Silencers ...

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Prothena has now earned $150 million to date of the $1.2 billion total ...

Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...

Supporting a loved one with transthyretin amyloidosis (ATTR-CM) to remain active involves encouraging familiar routines, managing energy levels, and fostering social connections to enhance their ...

The adjusted odds ratio for Alzheimer disease among people diagnosed with ATTR-CM was 0.65, suggesting a lower likelihood of developing the disease compared with controls. Transthyretin-mediated ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...